Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 43

Publication Record


Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages.
Mueller PA, Zhu L, Tavori H, Huynh K, Giunzioni I, Stafford JM, Linton MF, Fazio S
(2018) Circulation 138: 1850-1863
MeSH Terms: Animals, Aorta, Aortic Diseases, Apoptosis, Atherosclerosis, Cells, Cultured, Cholesterol, Disease Models, Animal, Female, Gene Deletion, Genetic Predisposition to Disease, Macrophages, Mice, Knockout, ApoE, Necrosis, Phenotype, Plaque, Atherosclerotic, Receptors, CCR7, Receptors, LDL, Signal Transduction, Tumor Suppressor Proteins, Up-Regulation
Show Abstract · Added July 20, 2018
BACKGROUND - We previously showed that mice lacking MΦLRP1 (low-density lipoprotein receptor-related protein 1 in macrophages) undergo accelerated atherosclerotic plaque formation due to changes in macrophages including increased apoptosis, decreased efferocytosis, and exaggerated transition to the inflammatory M1 phenotype. Here we sought to explore the role of macrophage low-density lipoprotein receptor-related protein 1 during regression of atherosclerosis since regressing plaques are characterized by transitioning of macrophages to M2 status as inflammation resolves.
METHODS - Apolipoprotein E mice on a high-fat diet for 12 weeks were reconstituted with bone marrow from apolipoprotein E-producing wild-type or MΦLRP1 mice, and then placed on a chow diet for 10 weeks (n=9 to 11 mice/group). A cohort of apolipoprotein E mice reconstituted with apolipoprotein E bone marrow served as baseline controls (n=9).
RESULTS - Plaques of both wild-type and MΦLRP1 bone marrow recipients regressed compared with controls (11% and 22%, respectively; P<0.05), and plaques of MΦLRP1 recipients were 13% smaller than those of wild-type recipients ( P<0.05). Recipients of MΦLRP1 marrow had 36% fewer M1 macrophages ( P<0.01) and 2.5-fold more CCR7 (C-C chemokine receptor type 7)-positive macrophages in the plaque relative to wild-type mice ( P<0.01). Additionally, in vivo studies of cellular egress showed a 4.6-fold increase in 5-ethynyl-2´-deoxyuridine-labeled CCR7 macrophages in mediastinal lymph nodes. Finally, in vivo studies of reverse cholesterol transport showed a 1.4-fold higher reverse cholesterol transport in MΦLRP1 recipient mice ( P<0.01).
CONCLUSIONS - Absence of macrophage low-density lipoprotein receptor-related protein 1 unexpectedly accelerates atherosclerosis regression, enhances reverse cholesterol transport, and increases expression of the motility receptor CCR7, which drives macrophage egress from lesions.
1 Communities
1 Members
0 Resources
21 MeSH Terms
Associations of coronary artery calcified plaque density with mortality in type 2 diabetes: the Diabetes Heart Study.
Raffield LM, Cox AJ, Criqui MH, Hsu FC, Terry JG, Xu J, Freedman BI, Carr JJ, Bowden DW
(2018) Cardiovasc Diabetol 17: 67
MeSH Terms: Adult, African Continental Ancestry Group, Aged, Aged, 80 and over, Coronary Angiography, Coronary Artery Disease, Coronary Vessels, Diabetes Mellitus, Type 2, European Continental Ancestry Group, Female, Humans, Male, Middle Aged, Plaque, Atherosclerotic, Prognosis, Risk Factors, United States, Vascular Calcification
Show Abstract · Added September 11, 2018
BACKGROUND - Coronary artery calcified plaque (CAC) is strongly predictive of cardiovascular disease (CVD) events and mortality, both in general populations and individuals with type 2 diabetes at high risk for CVD. CAC is typically reported as an Agatston score, which is weighted for increased plaque density. However, the role of CAC density in CVD risk prediction, independently and with CAC volume, remains unclear.
METHODS - We examined the role of CAC density in individuals with type 2 diabetes from the family-based Diabetes Heart Study and the African American-Diabetes Heart Study. CAC density was calculated as mass divided by volume, and associations with incident all-cause and CVD mortality [median follow-up 10.2 years European Americans (n = 902, n = 286 deceased), 5.2 years African Americans (n = 552, n = 93 deceased)] were examined using Cox proportional hazards models, independently and in models adjusted for CAC volume.
RESULTS - In European Americans, CAC density, like Agatston score and volume, was consistently associated with increased risk of all-cause and CVD mortality (p ≤ 0.002) in models adjusted for age, sex, statin use, total cholesterol, HDL, systolic blood pressure, high blood pressure medication use, and current smoking. However, these associations were no longer significant when models were additionally adjusted for CAC volume. CAC density was not significantly associated with mortality, either alone or adjusted for CAC volume, in African Americans.
CONCLUSIONS - CAC density is not associated with mortality independent from CAC volume in European Americans and African Americans with type 2 diabetes.
0 Communities
2 Members
0 Resources
18 MeSH Terms
Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers.
Leigh A, McEvoy JW, Garg P, Carr JJ, Sandfort V, Oelsner EC, Budoff M, Herrington D, Yeboah J
(2019) JACC Cardiovasc Imaging 12: 852-861
MeSH Terms: Aged, Aged, 80 and over, Atherosclerosis, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Early Detection of Cancer, Female, Humans, Incidence, Incidental Findings, Lung Neoplasms, Male, Middle Aged, Plaque, Atherosclerotic, Predictive Value of Tests, Prevalence, Prognosis, Radiography, Thoracic, Risk Assessment, Risk Factors, Smokers, Smoking, Time Factors, United States, Vascular Calcification
Show Abstract · Added January 10, 2020
OBJECTIVES - This study assessed the utility of the pooled cohort equation (PCE) and/or coronary artery calcium (CAC) for atherosclerotic cardiovascular disease (ASCVD) risk assessment in smokers, especially those who were lung cancer screening eligible (LCSE).
BACKGROUND - The U.S. Preventive Services Task Force recommended and the Centers for Medicare & Medicaid Services currently pays for annual screening for lung cancer with low-dose computed tomography scans in a specified group of cigarette smokers. CAC can be obtained from these low-dose scans. The incremental utility of CAC for ASCVD risk stratification remains unclear in this high-risk group.
METHODS - Of 6,814 MESA (Multi-Ethnic Study of Atherosclerosis) participants, 3,356 (49.2% of total cohort) were smokers (2,476 former and 880 current), and 14.3% were LCSE. Kaplan-Meier, Cox proportional hazards, area under the curve, and net reclassification improvement (NRI) analyses were used to assess the association between PCE and/or CAC and incident ASCVD. Incident ASCVD was defined as coronary death, nonfatal myocardial infarction, or fatal or nonfatal stroke.
RESULTS - Smokers had a mean age of 62.1 years, 43.5% were female, and all had a mean of 23.0 pack-years of smoking. The LCSE sample had a mean age of 65.3 years, 39.1% were female, and all had a mean of 56.7 pack-years of smoking. After a mean of 11.1 years of follow-up 13.4% of all smokers and 20.8% of LCSE smokers had ASCVD events; 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during the follow-up. One SD increase in the PCE 10-year risk was associated with a 68% increase risk for ASCVD events in all smokers (hazard ratio: 1.68; 95% confidence interval: 1.57 to 1.80) and a 22% increase in risk for ASCVD events in the LCSE smokers (hazard ratio: 1.22; 95% confidence interval: 1.00 to 1.47). CAC was associated with increased ASCVD risk in all smokers and in LCSE smokers in all the Cox models. The C-statistic of the PCE for ASCVD was higher in all smokers compared with LCSE smokers (0.693 vs. 0.545). CAC significantly improved the C-statistics of the PCE in all smokers but not in LCSE smokers. The event and nonevent net reclassification improvements for all smokers and LCSE smokers were 0.018 and -0.126 versus 0.16 and -0.196, respectively.
CONCLUSIONS - In this well-characterized, multiethnic U.S. cohort, CAC was predictive of ASCVD in all smokers and in LCSE smokers but modestly improved discrimination over and beyond the PCE. However, 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during follow-up.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
26 MeSH Terms
Genome-wide association study of coronary artery calcified atherosclerotic plaque in African Americans with type 2 diabetes.
Divers J, Palmer ND, Langefeld CD, Brown WM, Lu L, Hicks PJ, Smith SC, Xu J, Terry JG, Register TC, Wagenknecht LE, Parks JS, Ma L, Chan GC, Buxbaum SG, Correa A, Musani S, Wilson JG, Taylor HA, Bowden DW, Carr JJ, Freedman BI
(2017) BMC Genet 18: 105
MeSH Terms: African Americans, Coronary Vessels, Diabetes Mellitus, Type 2, European Continental Ancestry Group, Female, Genome-Wide Association Study, Genotype, Humans, Male, Middle Aged, Plaque, Atherosclerotic, Polymorphism, Single Nucleotide, Prevalence, United States, Vascular Calcification
Show Abstract · Added December 13, 2017
BACKGROUND - Coronary artery calcified atherosclerotic plaque (CAC) predicts cardiovascular disease (CVD). Despite exposure to more severe conventional CVD risk factors, African Americans (AAs) are less likely to develop CAC, and when they do, have markedly lower levels than European Americans. Genetic factors likely contribute to the observed ethnic differences. To identify genes associated with CAC in AAs with type 2 diabetes (T2D), a genome-wide association study (GWAS) was performed using the Illumina 5 M chip in 691 African American-Diabetes Heart Study participants (AA-DHS), with replication in 205 Jackson Heart Study (JHS) participants with T2D. Genetic association tests were performed on the genotyped and 1000 Genomes-imputed markers separately for each study, and combined in a meta-analysis.
RESULTS - Single nucleotide polymorphisms (SNPs), rs11353135 (2q22.1), rs16879003 (6p22.3), rs5014012, rs58071836 and rs10244825 (all on chromosome 7), rs10918777 (9q31.2), rs13331874 (16p13.3) and rs4459623 (18q12.1) were associated with presence and/or quantity of CAC in the AA-DHS and JHS, with meta-analysis p-values ≤8.0 × 10. The strongest result in AA-DHS alone was rs6491315 in the 13q32.1 region (parameter estimate (SE) = -1.14 (0.20); p-value = 9.1 × 10). This GWAS peak replicated a previously reported AA-DHS CAC admixture signal (rs7492028, LOD score 2.8).
CONCLUSIONS - Genetic association between SNPs on chromosomes 2, 6, 7, 9, 16 and 18 and CAC were detected in AAs with T2D from AA-DHS and replicated in the JHS. These data support a role for genetic variation on these chromosomes as contributors to CAC in AAs with T2D, as well as to variation in CAC between populations of African and European ancestry.
0 Communities
2 Members
0 Resources
15 MeSH Terms
Bilirubin Prevents Atherosclerotic Lesion Formation in Low-Density Lipoprotein Receptor-Deficient Mice by Inhibiting Endothelial VCAM-1 and ICAM-1 Signaling.
Vogel ME, Idelman G, Konaniah ES, Zucker SD
(2017) J Am Heart Assoc 6:
MeSH Terms: Animals, Antioxidants, Aorta, Bilirubin, Cell Movement, Collagen, Diet, Western, Intercellular Adhesion Molecule-1, Lipid Metabolism, Lymphocytes, Male, Mice, Mice, Knockout, Monocytes, Plaque, Atherosclerotic, Receptors, LDL, Signal Transduction, Vascular Cell Adhesion Molecule-1
Show Abstract · Added April 27, 2017
BACKGROUND - Numerous epidemiological studies support an inverse association between serum bilirubin levels and the incidence of cardiovascular disease; however, the mechanism(s) by which bilirubin may protect against atherosclerosis is undefined. The goals of the present investigations were to assess the ability of bilirubin to prevent atherosclerotic plaque formation in low-density lipoprotein receptor-deficient ( ) mice and elucidate the molecular processes underlying this effect.
METHODS AND RESULTS - Bilirubin, at physiological concentrations (≤20 μmol/L), dose-dependently inhibits THP-1 monocyte migration across tumor necrosis factor α-activated human umbilical vein endothelial cell monolayers without altering leukocyte binding or cytokine production. A potent antioxidant, bilirubin effectively blocks the generation of cellular reactive oxygen species induced by the cross-linking of endothelial vascular cell adhesion molecule 1 (VCAM-1) or intercellular adhesion molecule 1 (ICAM-1). These findings were validated by treating cells with blocking antibodies or with specific inhibitors of VCAM-1 and ICAM-1 signaling. When administered to mice on a Western diet, bilirubin (30 mg/kg intraperitoneally) prevents atherosclerotic plaque formation, but does not alter circulating cholesterol or chemokine levels. Aortic roots from bilirubin-treated animals exhibit reduced lipid and collagen deposition, decreased infiltration of monocytes and lymphocytes, fewer smooth muscle cells, and diminished levels of chlorotyrosine and nitrotyrosine, without changes in VCAM-1 or ICAM-1 expression.
CONCLUSIONS - Bilirubin suppresses atherosclerotic plaque formation in mice by disrupting endothelial VCAM-1- and ICAM-1-mediated leukocyte migration through the scavenging of reactive oxygen species signaling intermediaries. These findings suggest a potential mechanism for the apparent cardioprotective effects of bilirubin.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
0 Communities
1 Members
0 Resources
18 MeSH Terms
Coffee consumption and calcified atherosclerotic plaques in the coronary arteries: The NHLBI Family Heart Study.
Patel YR, Gadiraju TV, Ellison RC, Hunt SC, Carr JJ, Heiss G, Arnett DK, Pankow JS, Gaziano JM, Djoussé L
(2017) Clin Nutr ESPEN 17: 18-21
MeSH Terms: Adult, Aged, Coffee, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Coronary Vessels, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Plaque, Atherosclerotic, Prevalence, Risk Factors, United States, Vascular Calcification
Show Abstract · Added September 11, 2017
BACKGROUND & AIMS - While a recent meta-analysis of prospective studies reported that coffee consumption is associated with a lower risk of cardiovascular disease mortality, limited and inconsistent data are available on the relation of coffee intake with subclinical disease. Thus, the aim of the present study was to see the association of coffee consumption with the prevalence of atherosclerotic plaque in the coronary arteries in NHLBI Family Heart Study.
METHODS - In a cross-sectional design, we studied 1929 participants of the NHLBI Family Heart Study without known coronary heart disease. Coffee consumption was assessed by a semi-quantitative food frequency questionnaire and coronary-artery calcium (CAC) was measured by cardiac computed tomography. We defined prevalent CAC as an Agatston score of ≥100 and used generalized estimating equations to calculate prevalence ratios of CAC as well as a sensitivity analysis at a range of cutpoints for CAC.
RESULTS - Mean age was 56.7 years and 59% of the study subjects were female. In adjusted analysis for age, sex, BMI, smoking, alcohol, physical activity, field center, and energy intake, prevalence ratio (95% CI) for CAC was 1.0 (reference), 0.92 (0.57-1.49), 1.34 (0.86-2.08), 1.30 (0.84-2.02), and 0.99 (0.60-1.64) for coffee consumption of almost never, <1/day, 1/day, 2-3/day, and ≥4 cups/day, respectively. In a sensitivity analysis, there was no evidence of association between coffee consumption and prevalent CAC when CAC cut points of 0, 50, 150, 200, and 300 were used.
CONCLUSIONS - These data do not provide evidence for an association between coffee consumption and prevalent CAC in adult men and women.
Copyright © 2016 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
0 Communities
1 Members
0 Resources
17 MeSH Terms
Impact of vessel wall lesions and vascular stenoses on cerebrovascular reactivity in patients with intracranial stenotic disease.
Cogswell PM, Davis TL, Strother MK, Faraco CC, Scott AO, Jordan LC, Fusco MR, Frederick BD, Hendrikse J, Donahue MJ
(2017) J Magn Reson Imaging 46: 1167-1176
MeSH Terms: Adult, Aged, Aged, 80 and over, Atherosclerosis, Cerebral Arterial Diseases, Cerebral Arteries, Constriction, Pathologic, Female, Humans, Magnetic Resonance Angiography, Male, Middle Aged, Moyamoya Disease, Plaque, Atherosclerotic
Show Abstract · Added March 24, 2020
PURPOSE - To compare cerebrovascular reactivity (CVR) and CVR lagtimes in flow territories perfused by vessels with vs. without proximal arterial wall disease and/or stenosis, separately in patients with atherosclerotic and nonatherosclerotic (moyamoya) intracranial stenosis.
MATERIALS AND METHODS - Atherosclerotic and moyamoya patients with >50% intracranial stenosis and <70% cervical stenosis underwent angiography, vessel wall imaging (VWI), and CVR-weighted imaging (n = 36; vessel segments evaluated = 396). Angiography and VWI were evaluated for stenosis locations and vessel wall lesions. Maximum CVR and CVR lagtime were contrasted between vascular territories with and without proximal intracranial vessel wall lesions and stenosis, and a Wilcoxon rank-sum was test used to determine differences (criteria: corrected two-sided P < 0.05).
RESULTS - CVR lagtime was prolonged in territories with vs. without a proximal vessel wall lesion or stenosis for both patient groups: moyamoya (CVR lagtime = 45.5 sec ± 14.2 sec vs. 35.7 sec ± 9.7 sec, P < 0.001) and atherosclerosis (CVR lagtime = 38.2 sec ± 9.1 sec vs. 35.0 sec ± 7.2 sec, P = 0.001). For reactivity, a significant decrease in maximum CVR in the moyamoya group only (maximum CVR = 9.8 ± 2.2 vs. 12.0 ± 2.4, P < 0.001) was observed.
CONCLUSION - Arterial vessel wall lesions detected on noninvasive, noncontrast intracranial VWI in patients with intracranial stenosis correlate on average with tissue-level impairment on CVR-weighted imaging.
LEVEL OF EVIDENCE - 4 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2017;46:1167-1176.
© 2017 International Society for Magnetic Resonance in Medicine.
0 Communities
1 Members
0 Resources
MeSH Terms
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation.
Iwata H, Goettsch C, Sharma A, Ricchiuto P, Goh WW, Halu A, Yamada I, Yoshida H, Hara T, Wei M, Inoue N, Fukuda D, Mojcher A, Mattson PC, Barabási AL, Boothby M, Aikawa E, Singh SA, Aikawa M
(2016) Nat Commun 7: 12849
MeSH Terms: ADP-Ribosylation, Animals, Apoptosis, Atherosclerosis, Cell Survival, Coronary Artery Disease, Female, Humans, Inflammation, Interferon-gamma, Interleukin-4, Lipopolysaccharide Receptors, Macrophage Activation, Male, Mice, Mice, Inbred C57BL, Neoplasm Proteins, Phosphorylation, Plaque, Atherosclerotic, Poly(ADP-ribose) Polymerases, RAW 264.7 Cells, RNA Interference, Ribose, STAT1 Transcription Factor, THP-1 Cells
Show Abstract · Added March 14, 2018
Despite the global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscure. Here we show, with global proteomic analysis of macrophage cell lines treated with either IFNγ or IL-4, that PARP9 and PARP14 regulate macrophage activation. In primary macrophages, PARP9 and PARP14 have opposing roles in macrophage activation. PARP14 silencing induces pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells, whereas it suppresses anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppresses pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells. PARP14 induces ADP-ribosylation of STAT1, which is suppressed by PARP9. Mutations at these ADP-ribosylation sites lead to increased phosphorylation. Network analysis links PARP9-PARP14 with human coronary artery disease. PARP14 deficiency in haematopoietic cells accelerates the development and inflammatory burden of acute and chronic arterial lesions in mice. These findings suggest that PARP9 and PARP14 cross-regulate macrophage activation.
0 Communities
1 Members
0 Resources
25 MeSH Terms
The effect of high intensity statin use on liver density: A post hoc analysis of the coronary artery calcification treatment with zocor [CATZ] study.
Sarkar S, Terry JG, Ikizler TA, Crouse JR, Carr JJ, Hung AM
(2016) Obes Res Clin Pract 10: 613-615
MeSH Terms: Adult, Aged, Coronary Artery Disease, Disease Progression, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Plaque, Atherosclerotic, Radiography, Abdominal, Simvastatin, Tomography, X-Ray Computed, Treatment Outcome, Young Adult
Added September 29, 2016
0 Communities
2 Members
0 Resources
17 MeSH Terms
Bone Mineral Density and Progression of Subclinical Atherosclerosis in African-Americans With Type 2 Diabetes.
Wagenknecht LE, Divers J, Register TC, Russell GB, Bowden DW, Xu J, Langefeld CD, Lenchik L, Hruska KA, Carr JJ, Freedman BI
(2016) J Clin Endocrinol Metab 101: 4135-4141
MeSH Terms: Adipose Tissue, African Americans, Aortic Diseases, Atherosclerosis, Bone Density, Calcinosis, Carotid Artery Diseases, Comorbidity, Coronary Vessels, Diabetes Mellitus, Type 2, Disease Progression, Female, Humans, Male, Middle Aged, Plaque, Atherosclerotic
Show Abstract · Added September 29, 2016
CONTEXT - Relative to European Americans, calcified atherosclerotic plaque (CP) is less prevalent and severe in African-Americans (AAs).
OBJECTIVE - Predictors of progression of CP in the aorta, carotid, and coronary arteries were examined in AAs over a mean 5.3 ± 1.4-year interval.
DESIGN - This is the African American-Diabetes Heart Study.
SETTING - A type 2 diabetes (T2D)-affected cohort was included.
PARTICIPANTS - A total of 300 unrelated AAs with T2D; 50% female, mean age 55 ± 9 years, baseline hemoglobin A1c 8.1 ± 1.8% was included.
MAIN OUTCOME MEASURES - Glycemic control, renal parameters, vitamin D, and computed tomography-derived measures of adiposity, vascular CP, and volumetric bone mineral density (vBMD) in lumbar and thoracic vertebrae were obtained at baseline and follow-up.
RESULTS - CP increased in incidence and quantity/mass in all three vascular beds over the 5-year study (P < .0001). Lower baseline lumbar and thoracic vBMD were associated with progression of abdominal aorta CP (P < .008), but not progression of carotid or coronary artery CP. Lower baseline estimated glomerular filtration rate was associated with progression of carotid artery CP (P = .0004), and higher baseline pericardial adipose volume was associated with progression of coronary artery (P = .001) and aorta (P = .0006) CP independent of body mass index. There was a trend for an inverse relationship between change in thoracic vBMD and change in aortic CP (P = .05).
CONCLUSIONS - In this longitudinal study, lower baseline thoracic and lumbar vBMD and estimated glomerular filtration rate and higher pericardial adipose volumes were associated with increases in CP in AAs with T2D. Changes in these variables and baseline levels and/or changes in glycemic control, albuminuria, and vitamin D were not significantly associated with progression of CP.
0 Communities
1 Members
0 Resources
16 MeSH Terms